Key result
ADAMTS7 and ADAMTS12 protect against myxomatous valve degeneration by regulating matrix proteostasis and TGFβ signaling.
Key points are not available for this paper at this time.
Implicates ECM-TGFβ dysregulation in mutant valve pathology; leaves open whether ADAMTS7/12 targeting modifies disease.
valve leaflets reflects a complex disturbance of ECM proteostasis with accumulation of multiple ADAMTS7 and ADAMTS12 ECM substrates, and perturbation of regulatory pathways with roots in ECM, such as TGFβ signaling, which was increased in the mutant valves.
No takes yet. Share an insight, caveat, or question.
Mead et al. (2025) studied this question. ADAMTS7 and its homolog ADAMTS12 cooperate to protect against myxomatous valve degeneration by maintaining extracellular matrix proteostasis and regulating TGFβ signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: